US stocks2026-10-06 01:01:00U.S. stocks close higher as AI names advance, with Tempus AI up 9.03%According to data from MSX.COM, U.S. stocks finished higher, with the Dow Jones Industrial Average rising 0.18%, the S&P 500 gaining 0.66%, and the Nasdaq climbing 1.05%. The VIX also moved up 1.37% by the close. AI-related stocks broadly posted gains, led by Tempus AI, which rose 9.03%. Other names cited in the update included Atlassian, up 4.66%, Intuitive Surgical, up 3.71%, Astera Labs, up 3.43%, and Baidu, up 3.17%. The report also said MSX is a major RWA trading platform that has listed hundreds of RWA tokens, covering popular U.S. stock and ETF tokenized assets such as NVIDIA, GOOGL, MSFT, AMZN, META, TSM, and AMD.280
US stocks2026-09-18 01:01:00U.S. stocks close higher as AI names rally, with Tempus AI up 14.85%U.S. equities finished higher, according to data from MSX.COM, with all three major indexes ending the session in positive territory. The Dow Jones Industrial Average rose 0.61%, the S&P 500 gained 1.14%, and the Nasdaq climbed 1.69%. The VIX volatility index, often tracked as a fear gauge, fell 10.23% by the close. AI-related stocks posted broad gains. Tempus AI led the group with a 14.85% rise. Super Micro Computer added 9.5%, Astera Labs advanced 9.06%, Arm gained 8.57%, and Ambarella rose 6.6%. Odaily also noted that MSX is a major RWA trading platform. The platform has listed hundreds of RWA tokens tied to popular U.S. stocks and ETF underlyings, including Nvidia, GOOGL, MSFT, AMZN, META, TSM, and AMD. The figures cited in the report were attributed to MSX.COM data.550
cancer vaccin2026-09-08 02:20:09Tempus AI Could See Over $600M in Annual Revenue from Cancer Vaccine Sequencing, Analysts SayModerna and Merck's personalized cancer vaccines have added over $50 billion in market value to the two drugmakers. The diagnostic sequencing process behind these vaccines is emerging as a new investment opportunity. Tempus AI, as a sequencing partner for the Moderna-Merck vaccine, could benefit if the vaccine is approved. Piper Sandler estimates the melanoma vaccine alone could generate at least $50 million in annual sequencing revenue, while BTIG analyst Mark Massaro projects the figure could exceed $600 million. The post-treatment cancer recurrence monitoring market via blood tests is seen as a multi-billion-dollar opportunity, but Natera currently dominates. However, uncertainties remain in the mRNA cancer vaccine field, and pharma companies may internalize some sequencing work in the future.1110
Perpetual Con2026-08-28 21:18:49Binance Futures Lists Perpetuals for MARA, Tempus AI, IonQ, PDD and MerckBinance Futures has listed perpetual contracts for five global equities — bitcoin miner MARA, healthcare AI firm Tempus AI, quantum computing company IonQ, retailer PDD Holdings and pharmaceutical giant Merck — offering leverage up to 20x with 24/7 trading. MARA recently sold about one-third of its bitcoin reserves in a restructuring, raising $1.6 billion for data centers and AI infrastructure. Market analysis sees the listing as a bet on MARA's AI pivot rather than a pure bitcoin substitute. (via U.Today)960
Cathie Wood2026-08-27 17:15:22Cathie Wood Sells About $4 Million in Tempus AI Shares After 38% RiseARK Invest founder Cathie Wood recently sold about $4 million worth of Tempus AI shares, according to Techub News. The sale came after the stock had risen 38%. Crypto Briefing said the move was seen as a strategic adjustment aimed at managing fund liquidity during a period of investor outflows and market volatility. The report did not disclose additional details about the timing of the transaction beyond saying it was recent, nor did it provide the number of shares sold. The brief update centers on the size of the sale, the prior gain in Tempus AI, and the view that the reduction was tied to liquidity management rather than a broader explanation beyond what was cited.910
U.S. Stocks2026-08-25 01:00:08U.S. Stocks Close Mixed as AI Names Fall, Tempus AI Drops 8.97%U.S. stocks finished mixed on data from MSX.COM, with the Dow up 0.26%, the S&P 500 down 0.28%, the Nasdaq down 0.76%, and the VIX rising 4.76%. AI-related shares were broadly weaker. Tempus AI fell 8.97%, AeroVironment lost 7.5%, Micron dropped 5.83%, Super Micro Computer fell 5.56%, and Ambarella declined 5.06%. MSX said it is a leading RWA trading platform with hundreds of RWA tokens listed, including tokenized references tied to Nvidia, GOOGL, MSFT, AMZN, META, TSM, and AMD, as well as ETF token products.1320
U.S. stocks2026-08-22 01:00:13U.S. stocks close higher as AI names rally, Tempus AI jumps more than 9%U.S. stocks finished higher, with the Dow up 0.98%, the S&P 500 up 0.43%, and the Nasdaq up 0.43%, according to MSX.COM data. The VIX fell 5.5% at the close. AI-related stocks also moved higher, led by Tempus AI, which rose 9.06%. SoundHound AI gained 5.02%, while Snowflake, Palantir and EPAM also posted advances. MSX was described as a leading RWA trading platform with hundreds of RWA tokens already listed, covering tokenized names tied to Nvidia, GOOGL, MSFT, AMZN, META, TSM and AMD, along with ETF-related tokenized assets.1410
Moderna2026-08-21 02:05:21Moderna melanoma Phase 3 readout puts AI-driven drug development deeper into clinical and manufacturing workflowsModerna and Merck said on Aug. 19 that the Phase 3 INTerpath-001 trial delivered a positive topline readout in resected Stage IIB-IV melanoma, with Intismeran plus Keytruda showing statistically significant and clinically meaningful improvement in recurrence-free survival and distant metastasis-free survival versus Keytruda alone. The study enrolled 1,137 patients, but Moderna has not yet released the hazard ratios, absolute recurrence-rate differences, or overall survival data, so the only firm conclusion for now is that the Phase 3 study met its interim bar. The trial will continue rather than stop early. The report argues that the bigger story is operational. Intismeran is not a one-formula product for every patient. The therapy is built from each patient’s tumor and blood genetic information, with up to 34 neoantigens selected before a personalized mRNA treatment is produced. Moderna’s Maestro digital system coordinates clinical operations, manufacturing, quality control, and logistics across separate production batches. The article also points to upstream data work by Personalis, whose tumor analysis platform has been used by Moderna and Merck since the early V940/mRNA-4157 program, and notes Tempus AI’s planned acquisition of Personalis at about $1.5 billion enterprise value. It pairs that development with Anthropic’s recent protein-design experiment to show a broader shift: AI is moving out of stand-alone software and into real-world research, lab, production, and clinical processes.1570
